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Abstract
Purpose In contrast to other countries, the Dutch breast
cancer guideline does not recommend re-excision for
focally positive margins after breast-conserving surgery
(BCS) in invasive tumor and does recommend whole-
breast irradiation including boost. We investigated whether
omitting re-excision as compared to performing re-excision
affects prognosis with a retrospective population-based
cohort study.
Methods The total cohort included 32,119 women with
primary BCS for T1–T3 breast cancer diagnosed between
2003 and 2008 from the nationwide Netherlands cancer
registry. The subcohort included 10,433 patients in whom
the resection margins were registered. Outcome measures
were 5-year ipsilateral breast tumor recurrence (IBTR) rate,
5-year disease-free survival (DFS) rate, and 10-year overall
survival (OS) rate.
Results In the total cohort, 25,878 (80.6%) did not have re-
excision, 2368 (7.4%) had re-excision by BCS, and 3873
(12.1%) had re-excision by mastectomy. Five-year IBTR
rates were 2.1, 2.8, and 2.9%, respectively (p = 0.001). In
the subcohort, 7820 (75.0%) had negative margins without
re-excision, 492 (4.7%) had focally positive margins
without re-excision, 586 (5.6%) had focally positive mar-
gins and underwent re-excision, and 1535 (14.7%) had
extensively positive margins and underwent re-excision.
Five-year IBTR rate was 2.3, 2.9, 1.1, and 2.9%, respec-
tively (p = 0.099). Compared to omitting re-excision,
performing re-excision for focally positive margins was
associated with lower risk of IBTR (adjusted HR 0.30, 95%
CI 0.11–0.82), but not with DFS (adjusted HR 0.83 95% CI
0.59–1.17) nor with OS (adjusted HR 1.17 95% CI
0.87–1.59).
Conclusion Omitting re-excision in breast cancer patients
for focally positive margins after BCS does not impair DFS
and OS, provided that whole-breast irradiation including
boost is given.
Keywords Breast-conserving surgery  Resection
margins  Re-excision  Re-operation  Ipsilateral breast
tumor recurrence  Disease-free survival  Overall survival
Introduction
For breast-conserving surgery (BCS), the minimally
accepted resection margin above which a re-excision will
be advised has been debated extensively since high level of
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Table 1 Clinicopathological and treatment characteristics according to the performance of re-excision in the total cohort (n = 32119)
Primary BCS
only
Primary BCS ? re-excision by
BCS
Primary BCS ? re-excision by
mastectomy
p valuea
No. of patients 25878 (80.6) 2368 (7.4) 3873 (12.1)
Age \0.001
[60 years 10505 (40.6) 718 (30.3) 1185 (30.6)
51–60 years 7946 (30.7) 780 (32.9) 1113 (28.7)
41–50 years 5795 (22.4) 681 (28.8) 1152 (29.7)
B40 years 1632 (6.3) 189 (8.0) 423 (10.9)
Histology \0.001
Ductal 20148 (77.9) 1797 (77.9) 2548 (65.8)
Lobularb 2841 (11.0) 325 (13.7) 901 (23.3)
Other 2889 (11.2) 246 (10.4) 424 (10.9)
Differentiation grade \0.001
1 6657 (25.7) 550 (23.2) 606 (15.6)
2 10726 (41.4) 985 (41.6) 1611 (41.6)
3 7086 (27.4) 657 (27.7) 1281 (33.1)
Unknown 1409 (5.4) 176 (7.4) 375 (9.7)
pT \0.001
T1 19289 (74.5) 1730 (73.1) 2164 (55.9)
T2 6463 (25.0) 631 (26.6) 1493 (38.5)
T3 51 (0.2) 6 (0.3) 216 (5.6)
ypT0 75 (0.3) 1 (0.0) –
pN \0.001
N0 18200 (70.3) 1589 (67.1) 1998 (51.6)
N1 5944 (23.0) 620 (26.2) 1284 (33.2)
N2 1045 (4.0) 104 (4.4) 375 (9.7)
N3 432 (1.7) 35 (1.5) 183 (4.7)
Unknown 257 (1.0) 20 (0.8) 33 (0.9)
Oestrogen receptor \0.001
Positive 13508 (52.2) 1267 (53.5) 1803 (46.6)
Negative 2720 (10.5) 230 (9.7) 422 (10.9)
Unknown 9650 (37.3) 871 (36.8) 1648 (42.6)
Progesterone receptor \0.001
Positive 10836 (41.9) 996 (42.1) 1414 (36.5)
Negative 4874 (18.8) 424 (17.9) 725 (18.7)
Unknown 10168 (39.3) 948 (40.0) 1734 (44.8)
HER2Neu receptor \0.001
Negative 13282 (51.3) 1220 (51.5) 1647 (42.5)
Positive 1761 (6.8) 183 (7.7) 404 (10.4)
Unknown 10835 (41.9) 965 (40.8) 1822 (47.0)
Systemic therapyc \0.001
None 13128 (51.1) 1114 (47.0) 1321 (34.1)
Chemotherapy only 3173 (12.3) 286 (12.1) 565 (14.6)
Hormonal therapy only 4038 (15.6) 332 (14.0) 616 (15.9)
Chemotherapy and hormonal
therapy
5449 (21.1) 636 (26.9) 1371 (35.4)
pT pathological tumor stage, pN regional lymph nodes stage
a v2 test
b Includes mixed ductal and lobular tumors
c Both neoadjuvant and adjuvant
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evidence is lacking. For many years, the international
debate has been predominated by finding the ideal negative
margin width, whereby it was compared to positive margins
in general. A meta-analysis concluded that there is no evi-
dence that increasing the tumor-free margin width signifi-
cantly reduces the odds of local recurrence [1]. Since a
tumor-positive margin did increase the odds of local
recurrence, the Society of Surgical Oncology and the
American Society for Radiation Oncology (SSO-ASTRO)
and European Society for Medical Oncology (ESMO)
recently published guidelines recommending no ink on
tumor as an adequate margin for invasive breast cancer. Re-
excision is only advised in case the tumor is touching the
inked resection margin [2, 3]. No distinction was made,
however, between focally and extensively positive margins.
The next question in the debate is whether a focally
positive margin is a risk factor for local recurrence and
therefore an indication for re-excision. Six out of seven
studies previously investigating local recurrence rate in
patients with focally positive margins after final surgery
found it was not different from negative margins [4–10]. In
the last decade, the risk of local recurrence has decreased
even more through improvements in radiotherapy and
systemic treatment [11]. The impact of margin status on
local relapse was also investigated in the European
Organisation for Research and Treatment of Cancer
(EORTC) boost versus no boost trial. Margin status had no
significant influence, suggesting that radiotherapy boost on
the tumor bed negates the prognostic significance of posi-
tive margins [12, 13].
Uniquely, since 2002, the Dutch national guideline does
not recommend a re-excision for focally positive margins
after BCS in case of invasive disease and does recommends
to apply whole-breast radiotherapy including a boost on the
tumor bed in this situation [14]. As far as we know, the
Netherlands is the only country with such a liberal
approach. How often re-excision is indeed omitted in
clinical practice is unknown [15]. The aim of the current
study was to describe the implementation of the recom-
mendation in clinical practice and investigate whether
omitting re-excision for focally positive margins affects
ipsilateral breast tumor recurrence (IBTR), disease-free
survival (DFS), and overall survival (OS) in a nationwide
cancer registry.
Methods
In this retrospective population-based cohort study, all
female invasive breast cancer patients diagnosed between
2003 and 2008 with BCS as their primary surgical treat-
ment in the Netherlands were included. Data were retrieved
from the Netherlands Cancer Registry that includes all new
cancer diagnoses in the Netherlands since 1989 covering
17 million inhabitants. The main source of information is
the national pathology archive and in addition the registry
is linked with the national discharge register. Specially
trained registration clerks from the Netherlands Cancer
Registry are located in each hospital in the Netherlands,
both academic and non-academic, and independently col-
lect data on patient demographics, tumor characteristics,
and breast cancer treatment. Data completeness exceeds
95% [16]. The registration clerks follow a strict coding
manual of which the majority is mandatory to register.
Registration of resection margins was optional and it was
not collected by all registration clerks. Death certificates
are not available, due to privacy regulations. Vital status
and date of death are obtained by a yearly linkage to the
Excluded:
- cM1 or pM1 (n=275)
- pTX, pT0 or pT4 (n=503)
- no adjuvant radiotherapy after final BCS (n=1,186)
- prior malignancy§ (n=2,643)
- bilateral breast cancer at presentation (n=366)
- 5-year follow-up of disease recurrence not registered
(n=5,564)*
Total cohort (n=32,119):
- primary BCS only: n=25,878
- primary BCS + re-excision by BCS: n=2,368
- primary BCS + re-excision by mastectomy: n=3,873
Excluded:
- resection margins after primary BCS not registered 
(n=21,206)
- negative margins but with re-excision (n=322)
- extensively positive margins but without re-excision 
(n=158)
Patient selection from the Netherlands Cancer Registry: 
females with breast conserving surgery as primary surgical 
treatment for an invasive breast cancer diagnosed between 
2003-2008 (n=42,656)
Subcohort (n=10,433):
- negative margins: n=7,820
- focally positive margins: n=1,078
- extensively positive margins: n=1,535
Fig. 1 Patient selection. cM1 clinically suspect distant metastasis,
pM1 pathologically confirmed distant metastasis, pTX primary tumor
cannot be assessed or is unknown, pT0 no evidence of primary tumor,
pT4 tumor with direct extension to the chest wall and/or to the skin,
BCS breast-conserving surgery. §Except for basal-like skin cancer.
*Follow-up information on disease recurrence was assembled for all
patients diagnosed in 2003–2006, and for 44% of the patients
diagnosed in 2007–2008 due to lack of funding for some hospitals. 
All patients of whom the breast was conserved had adjuvant
radiotherapy. From all patients with a re-excision by mastectomy,
873 (22.5%) had adjuvant radiotherapy. Since it was an optional item
in the coding manual, some registration clerks did not code margins
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Municipal Personal Records Database and are complete up
to December 31, 2014. Information on local, regional, and
contralateral recurrence as well as distant metastasis is not
collected routinely by the cancer registry. On a project
basis, it was collected retrospectively by the local regis-
tration clerks up to 5 years after primary breast cancer
diagnosis for the cohort diagnosed between 2003 and 2008.
The exclusion criteria are shown in Fig. 1.
Definitions
Clinical and pathological tumor node metastasis staging
(TNM) was in accordance with the sixth edition of TNM
Classification of Malignant Tumors by the American Joint
Committee on Cancer (AJCC). Surgical treatment was
classified as ‘primary BCS only’ for patients who under-
went BCS not followed by a re-excision. Patients who
underwent BCS followed by a re-excision were classified
as ‘re-excision by BCS’ or ‘re-excision by mastectomy’
according to the type of final re-excision. Margin status
was classified as ‘negative’ defined as no invasive tumor
component and/or adjacent DCIS component touching the
inked margin, ‘focally positive’ defined as foci of invasive
tumor component and/or adjacent DCIS component
touching the inked margin over a length of four mm or less,
or ‘extensively positive’ defined as foci of invasive tumor
component and/or adjacent DCIS component touching the
inked margin over a length of more than four mm. The
four-mm cut-off is a translation from the previous defini-
tion of three low-power microscopic fields (using a 910
ocular lens). All Dutch pathologists are obliged to report
the margin status by this classification. The use of radio-
therapy was registered as yes or no, but details about the
total dose, anatomical fields, and use of boost were not
included in the registry.
The first recurrence that occurred at least 3 months from
primary breast cancer diagnosis was registered by the
Netherlands Cancer Registry. Other recurrence(s) within 3
months from the first recurrence were also included. IBTR
rate was defined as the percentage of patients with ipsi-
lateral local recurrence of breast carcinoma. DFS rate was
defined as the percentage of patients being alive without
having had any breast cancer recurrence (i.e., local,
regional, contralateral, or distant). OS rate was defined as
the percentage of patients being alive.
Dutch national breast cancer guideline
The Dutch guideline is evidence-based and complemented
with expert opinion written by a multidisciplinary team and
is regularly updated. The goal is to advise and guide
clinical practice. In the timeframe studied, it recommended
whole-breast irradiation with a doses equivalence of 50 Gy
followed by a 14–16 Gy boost in case of negative margins.
Boost could be omitted in patients older than 60 years. In
case of focally positive margins or patients being 40 years
or younger with negative margins, a 20–25 Gy boost was
recommended. Post-mastectomy chest wall irradiation was
recommended in case of positive margins, tumor growth
into the pectoral muscle, and should be considered for T3
tumors, with a doses equivalence of 45–50 or 60–70 Gy in
case of macroscopic residual tumor. Regional lymph node
irradiation was indicated in case of pN2 or if the highest
axillary medial node was positive.
Statistical analysis
To avoid noise in the comparisons between groups that are
defined by the patient’s margin status and surgical treat-
ment, patients were excluded if they had re-excision for
negative margins and if they did not had re-excision for
extensively positive margins (Fig. 1). Primary outcome
was IBTR and secondary outcomes were DFS and OS. The
effect of re-excision and type of re-excision (i.e., BCS or
mastectomy) on the outcomes was studied in the total
cohort (32,119 patients), irrespective of the resection
margins after primary BCS. Subsequently, the effect of
resection margins on the outcomes was studied in a sub-
cohort (10,433 patients) of whom the resection margins
after primary BCS were registered (Fig. 1). Time of fol-
low-up was defined as the time between the latest re-ex-
cision and the event or censoring. Patients were censored in
case of emigration, 5 years after the latest breast cancer
operation concerning IBTR and DFS, or at the December
31, 2014 concerning OS. Differences in patient character-
istics were tested using the v2 test. IBTR rate, DFS rate,
and OS rate were determined by Kaplan–Meier method and
distributions between subgroups were compared by the log-
rank test. Hazard ratios (HR) were estimated by Cox pro-
portional hazards regression analysis. In the total cohort,
comparisons were made with respect to whether or not a re-
excision was performed. In the subcohort, comparisons
were made with respect to resection margins including
whether or not a re-excision was performed. Due to the
prognostic importance of systemic therapy, the effect of
margin status on IBTR was also studied after stratification
for use of (neo)adjuvant systemic therapy (none versus
endocrine therapy and/or chemotherapy). Multivariable
models were performed by the enter method (i.e., including
all covariates at the same time in the model and no forward
or backward selection) and included all clinicopathological
and treatment variables with a maximum degrees of free-
dom of ten events per covariate included. Missing values
were classified as unknown. In spite of missing values, all
patients were included in the analyses to prevent bias in
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IBTR, DFS, and OS rate estimates. Interaction was tested
between all variables and margin status for IBTR. The
proportional hazards assumption was tested by graphing
the log(-log(IBTR)) versus log of IBTR time of each
variable in Table 1 and was considered proportional when
parallel curves were observed. Statistical tests were two-
sided, and p value\0.050 was considered statistically
significant. SPSS version 21 (IBM, Armonk, New York,
USA) was used for all statistical analyses.
Results
Re-excision in total cohort
Of the total of 42,656 women with invasive breast cancer
diagnosed between 2003 and 2008 and primarily treated
with BCS in the Netherlands, 32,119 met the eligibility
criteria. Patient selection is displayed in Fig. 1. Patients in
whom no 5-year follow-up was collected due to lack of
funding did not differ from the total cohort in terms of
clinicopathological and treatment characteristics. Re-exci-
sion was performed in 6241 (19.4%) patients of whom
3873 (62.1%) underwent a mastectomy. The frequency of
mastectomy as the re-excision decreased over time from
65.9% in 2003 to 52.5% in 2008. Clinicopathological and
treatment characteristics are shown in Table 1. All patients
with primary BCS only and re-excision by BCS have had
radiotherapy. From the 3873 patients with re-excision by
mastectomy, 873 (22.5%) had radiotherapy. Median fol-
low-up time for IBTR, DFS, and OS was 60 months (in-
terquartile range (IQR) 57–60), 60 months (IQR 57–60),
and 106 months (86–123), respectively. After testing the
proportional hazards assumption for all variables as shown
in Table 1, a constant relative hazard was seen for IBTR
risk and therefore time was not included in the multivari-
able models. The 5-year IBTR rate in the primary BCS
only, re-excision by BCS, and re-excision by mastectomy
group was 2.1, 2.8, and 2.9%, respectively (p = 0.001)
(Table 2). Multivariable analysis showed that IBTR rates
after re-excision by BCS and re-excision by mastectomy
were not statistically significantly different as compared to
primary BCS only (HR 1.31 95% CI 1.00–1.71 and HR
0.89 95% CI 0.57–1.40, respectively). DFS rates and OS
rates are shown in Table 2 and were statistically signifi-
cantly decreased in patients with re-excision by mastec-
tomy as compared to primary BCS only after multivariable
analyses.
Resection margins in subcohort
The subcohort consisted of 10,433 (32.5%) patients
(Fig. 1). The registration of resection margin in the cancer
registry was not associated with the occurrence of IBTR
(OR 1.12 95% CI 0.95–1.31 p = 0.180). Clinicopatho-
logical and treatment characteristics are shown in Table 3.
Negative margins were observed in 7820 (75.0%) patients,
focally positive margins in 1078 (10.3%) patients, and
extensively positive margins in 1535 (14.7%) patients.
After focally positive margins, in 492 (45.6%) patients, re-
excision was omitted (i.e., primary BCS only) and in 586
(54.4%) patients re-excision was performed. The frequency
of omitting the re-excision varied non-linearly over time
ranging between 32.8 and 58.4% and the proportional
hazards assumption for IBTR was not violated. Figure 2
shows the use of re-excision in the patients with focally
positive margins according to whether the invasive com-
ponent and/or the adjacent DCIS component were focally
Table 2 Ipsilateral breast tumor recurrence (IBTR), disease-free
survival (DFS), and overall survival (OS) rates from Kaplan–Meier
analysis and adjusted hazard ratio (HR) from multivariable Cox
regression analysis according to the performance of re-excision in the
total cohort (n = 32119)
IBTR DFS OS
5-year
(%)
Adjusteda HR
(95% CI)
5-year
(%)
Adjusteda HR
(95% CI)
5-year
(%)
10-year
(%)
Adjusteda HR
(95% CI)
Primary BCS only (n = 25878)b 2.1 Reference 89.0 Reference 92.7 82.1 Reference
Primary BCS ? re-excision by BCS
(n = 2368)b
2.8 1.31 (1.00–1.71) 87.7 1.13 (1.00–1.28) 94.5 85.3 0.89 (0.80–1.00)
Primary BCS ? re-excision by
mastectomy (n = 3873)c
2.9 0.89 (0.57–1.40) 82.9 1.38 (1.19–1.61) 89.9 78.7 1.16 (1.01–1.34)
Italic values indicate p\ 0.05
a Adjusted for: age (continuous), histology (ductal, lobular, or other), differentiation grade (1, 2, 3, or unknown), pT stage (1, 2, 3, or ypT0), pN
stage (1, 2, 3, or unknown), estrogen receptor status (positive, negative, or unknown), HER2Neu receptor status (positive, negative, or unknown),
use of systemic therapy (any or none), and radiotherapy (yes or no)
b All patients had radiotherapy (100%)
c Radiotherapy was performed in 873 (22.5%) of the patients
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Table 3 Clinicopathological and treatment characteristics according to resection margin after primary BCS and the performance of re-excision
in the subcohort (n = 10433)
Negative margin and
primary BCS only
Focally positive margin
and primary BCS only
Focally positive margin and
primary BCS ? re-excisiona
Extensively positive margin and
primary BCS ? re-excisionb
p value
Total no. of
patients
7820 (75.0) 492 (4.7) 586 (5.6) 1535 (14.7)
Age \0.001
[60 years 2695 (34.5) 210 (42.7) 149 (25.4) 374 (24.4)
51–60 years 2346 (30.0) 120 (24.4) 169 (28.8) 417 (27.2)
41–50 years 2258 (28.9) 145 (29.5) 218 (37.2) 583 (38.0)
B40 years 521 (6.7) 17 (3.5) 50 (8.4) 161 (10.5)
Histology \0.001
Ductal 6233 (79.7) 379 (77.0) 427 (72.9) 1046 (68.2)
Lobularc 783 (10.0) 69 (13.8) 110 (18.8) 317 (20.6)
Other 804 (10.3) 45 (9.1) 49 (8.4) 172 (11.2)
Differentiation grade \0.001
1 1766 (22.6) 105 (21.3) 94 (16.0) 254 (16.5)
2 3114 (39.8) 202 (41.1) 229 (39.1) 618 (40.3)
3 2440 (31.2) 149 (30.3) 217 (37.0) 506 (33.0)
Unknown 500 (6.4) 36 (7.3) 46 (7.8) 157 (10.2)
pT \0.001
T1 5576 (71.3) 345 (70.1) 347 (59.2) 866 (56.4)
T2 2123 (27.1) 145 (29.5) 227 (38.7) 593 (38.6)
T3 15 (0.2) 2 (0.4) 12 (2.0) 76 (5.0)
ypT0 34 (0.4) – – –
pN \0.001
N0 5166 (66.1) 316 (64.2) 297 (50.7) 816 (53.2)
N1 2231 (27.4) 117 (23.8) 214 (36.5) 503 (32.8)
N2 344 (4.4) 40 (8.1) 47 (8.0) 142 (9.3)
N3 120 (1.5) 17 (3.5) 25 (4.3) 61 (3.9)
Unknown 67 (0.9) 2 (0.4) 3 (0.5) 13 (0.8)
Oestrogen receptor \0.001
Positive 3292 (42.1) 217 (44.1) 245 (41.8) 531 (34.6)
Negative 710 (9.1) 42 (8.5) 55 (9.4) 124 (8.1)
Unknown 3818 (48.8) 233 (47.4) 286 (48.8) 880 (57.3)
Progesterone receptor \0.001
Positive 2662 (34.0) 176 (35.8) 182 (31.1) 410 (26.7)
Negative 1253 (16.0) 81 (16.5) 103 (17.6) 227 (14.8)
Unknown 3905 (49.9) 235 (47.8) 301 (51.4) 898 (58.5)
HER2Neu receptor \0.001
Negative 3890 (37.0) 188 (38.2) 196 (33.4) 392 (25.5)
Positive 980 (12.5) 68 (13.8) 96 (16.4) 233 (15.2)
Unknown 3950 (50.5) 236 (48.0) 294 (50.2) 910 (59.3)
Systemic therapyd \0.001
None 3214 (41.1) 183 (37.2) 179 (29.0) 468 (30.5)
Chemotherapy
only
1011 (12.9) 53 (10.8) 82 (14.0) 225 (14.7)
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touching the inked margins. Of the 586 patients with
focally positive margins and re-excision, 268 (45.7%)
underwent a re-excision by BCS followed by adjuvant
radiotherapy and 318 (54.3%) underwent a re-excision by
mastectomy of whom 84 (26.4%) had post-mastectomy
radiotherapy. The type of re-excision varied non-linearly
over time with the frequency of BCS ranging between 40.7
and 53.3%.
Ipsilateral breast tumor recurrence (IBTR)
After a median follow-up time of 60 months (IQR
59–60), 222 IBTR’s occurred. Five-year IBTR rate was
2.3% in patients with negative margin and primary BCS
only, 2.9% in patients with focally positive margin and
primary BCS only, 1.1% in patients with focally positive
margin and re-excision, and 2.9% in patients with
extensively positive margin and re-excision (p = 0.099)
(Table 4). Interaction between all clinicopathological and
treatment characteristics with margin status was tested but
none interacted statistically significantly. Multivariable
analyses showed that performing re-excision in patients
with focally positive margins was statistically signifi-
cantly associated with a lower IBTR rate as compared to
omitting re-excision (adjusted HR 0.30 95% CI
0.11–0.82); however the absolute difference in 5-year
IBTR rate was low 1.8% (2.9–1.1%).
Disease-free survival (DFS)
After a median follow-up time of 60 months (IQR 59–60),
1181 patients developed recurrent disease. Five-year DFS
rates are shown in Table 4. Multivariable analyses showed
that performing re-excision in patients with focally positive
margins was not associated with improved DFS as com-
pared to omitting re-excision (adjusted HR 0.83 95% CI
0.59–1.17).
Table 3 continued
Negative margin and
primary BCS only
Focally positive margin
and primary BCS only
Focally positive margin and
primary BCS ? re-excisiona
Extensively positive margin and
primary BCS ? re-excisionb
p value
Hormonal
therapy only
1168 (14.9) 83 (16.9) 79 (13.5) 180 (11.7)
Chemotherapy
and
hormonal
therapy
2427 (31.0) 173 (35.2) 255 (43.5) 662 (43.1)
Radiotherapy 7820 (100) 492 (100) 352 (60.1) 786 (51.2) \0.001
pT pathological tumor stage, pN regional lymph nodes stage
a Re-excision by BCS in 268 (45.7%) patients of whom all had radiotherapy (100%) and re-excision by mastectomy in 318 (54.3%) patients of
whom 84 (26.4%) had radiotherapy
b Re-excision by BCS in 516 (33.7%) patients whom all had radiotherapy (100%) and re-excision by mastectomy in 1016 (66.3%) patients of
whom 270 (26.5%) had radiotherapy
c Includes mixed ductal and lobular tumors
d Both neoadjuvant and adjuvant
Fig. 2 Re-excisions according to the tumor component focally
touching the inked margin. Figure only shows the patients with
focally positive margins after primary BCS from the subcohort
(n = 1078). Re-excision was omitted in 492 (45.6%) patients (total of
blue bars) and was performed in 586 (54.4%) patients (total of orange
and red bars). The frequency and type of re-excision is shown
according to which component of the tumor was focally touching the
inked margin
Breast Cancer Res Treat
123
Overall survival (OS)
After a median follow-up time of 110 months (IQR
78–135), 1709 deaths of any cause occurred. Five- and
10-year OS rates are shown in Table 4. Multivariable
analyses showed that performing re-excision in patients
with focally positive margins was not associated with
improved OS as compared to omitting re-excision (ad-
justed HR 1.17 95% CI 0.87–1.59).
Systemic therapy
Stratifying the subcohort into patients who did (6398
patients) and did not (4035 patients) had (neo) adjuvant
systemic therapy showed that 5-year IBTR rate was always
lower than 4.0% independent of margin status and use of
re-excision (see Online Resource 1, Table 2). In patients
with systemic therapy, performing re-excision for focally
positive margins was not statistically significantly associ-
ated with lower IBTR as compared to omitting re-excision
(unadjusted HR 0.28 95% CI 0.08–1.06). In patients
without systemic therapy, performing re-excision for
focally positive margins was not statistically significantly
associated with lower IBTR as compared to omitting re-
excision (unadjusted HR 0.61 95% CI 0.15–2.56). After
selecting patients with focally positive margins and pri-
mary BCS only, use of systemic therapy was not statisti-
cally significantly associated with lower IBTR compared to
no use of systemic therapy (unadjusted HR 0.92 95% CI
0.30–2.81).
Discussion
Omitting re-excision for focally positive margins was
associated with statistically significantly higher IBTR rate
as compared to performing re-excision (adjusted HR 0.30
95% CI 0.11–0.82), but the absolute difference was small
(1.8% at 5-years), the absolute number of events was
already low in both groups (2.9% versus 1.1% at 5-years),
and the odds ratio was not significantly different from
negative margins. Moreover, omitting re-excision in case
of focally positive margins did not adversely affect DFS
and OS. In the total study population (n = 32119) irre-
spective of the margins, IBTR rate was similar for patients
with primary BCS only and patients with re-excision.
Table 4 Ipsilateral breast tumor recurrence (IBTR), disease-free
survival (DFS), and overall survival (OS) rates from Kaplan–Meier
analysis and adjusted hazard ratio (HR) from multivariable Cox
regression analysis according to resection margins after primary BCS
and the performance of re-excision in the subcohort (n = 10433)
IBTR DFS OS
5-year Adjusteda HR
(95% CI)
5-year
(%)
Adjusteda HR
(95% CI)
5-year
(%)
10-year
(%)
Adjusteda HR
(95% CI)
Negative margins and primary BCS only
(n = 7820)b
163
(2.3%)
0.76
(0.43–1.35)
89.2 0.81
(0.63–1.04)
93.1 82.9% 1.07
(0.85–1.34)
Focally positive margins
Primary BCS only (n = 492)b 13
(2.9%)
Reference 86.0 Reference 92.7 81.1 Reference
Primary BCS ? re-excision (n = 586)c 6 (1.1%) 0.30 (0.11–
0.82)
87.1 0.83
(0.59–1.17)
92.1 82.1 1.17
(0.87–1.59)
By BCS (n = 268)b 3 (1.3%) 0.39
(0.11–1.38)
90.7 0.66
(0.42–1.06)
94.8 86.0 1.01
(0.68–1.49)
By mastectomy (n = 318)d 3 (1.0%) 0.23 (0.06–
0.89)
84.0 0.98
(0.66–1.47)
89.9 78.7 1.34
(0.93–1.91)
Extensively positive margins and primary
BCS ? re-excision (n = 1535)e
40
(2.9%)
0.75
(0.37–1.51)
84.7 0.97
(0.72–1.31)
91.8 81.1 1.22
(0.94–1.59)
Italic values indicate p\ 0.05
a Adjusted for: age (continuous), histology (ductal, lobular, or other), differentiation grade (1, 2, 3, or unknown), pT stage (1, 2, 3, or ypT0), pN
stage (1, 2, 3, or unknown), estrogen receptor status (positive, negative, or unknown), HER2Neu receptor status (positive, negative, or unknown),
use of systemic therapy (any or none), and radiotherapy (yes or no). Complete table can be found in the Online Resource 1, Table 1
b Radiotherapy was performed in all patients with BCS (100%)
c Radiotherapy was performed in 352 (60.1%) of the patients since all 268 patients with re-excision by BCS (100%) and 84 (26.4%) of the
patients with re-excision by mastectomy had radiotherapy
d Radiotherapy was performed in 84 (26.4%) patients
e Adjuvant radiotherapy was performed in 786 (51.2%) patients since all 516 patients with re-excision by BCS (100%) and 270 (26.5%) of the
patients with re-excision by mastectomy had radiotherapy
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Therefore, it can be concluded that omitting re-excision for
focally positive margins does not impair DFS and OS. It
could be argued that the difference found in IBTR rate is
not clinically relevant; however, more evidence is needed
to confirm this. Introducing the policy to omit re-excision
for focally positive margins could potentially prevent large
numbers of mastectomies which accounted for over 50% of
the re-excisions. Interestingly, comparing IBTR, DFS, and
OS rates between the re-excision by BCS group and re-
excision by mastectomy group in the total study population
(Table 2), it suggests that mastectomy is not preferred over
BCS. Less mastectomies and attendant breast reconstruc-
tions will reduce burden to the patient and health-care costs
that have been estimated to be $1055 per patient attempting
BCS [17]. The same holds for the costly procedure of
cavity shaving that has recently been introduced since our
high rate of local control in patients with involved margins
suggests it is unnecessary [18, 19].
Both the SSO/ASTRO guideline and the meta-analysis
that was the guideline’s primary evidence base do not
separate positive margins into focally or extensively posi-
tive. Six studies that did describe prognosis in patients with
focally positive margins previously were all unicenter,
predominantly from the 1980s, and margin status was
defined after the final surgery and not after the first surgery
[4–7, 9, 10]. They included only between 10 and 124
patients with focally positive margins who had whole-
breast irradiation with a total dose range 55–65 Gy. Five-
and eight-year local recurrence rates were reported by four
studies and two studies, respectively, and ranged between 2
and 15% and 10–14%, respectively. Five out of six studies
found that margin status after final excision was not sta-
tistically significantly associated with local recurrence after
unadjusted analyses. These studies were too small to
compare their findings to ours.
Our hypothesis is that radiotherapy boost reduces IBTR
rates and nullifies the prognostic influence of focally pos-
itive margins. Jones et al. showed that a positive margin
after BCS not followed by a re-excision was not a risk
factor for local relapse in the boost versus no boost trial
[12]. All patients with final BCS in our study population
underwent adjuvant whole-breast radiotherapy, since no
radiotherapy after BCS was an exclusion criterion. Unfor-
tunately, what patients actually received and if boost was
included was not registered by the Netherlands Cancer
Registry. The Dutch guideline has strict recommendations,
however, regarding radiotherapy (see methods), but whe-
ther they were strictly followed is unknown. To estimate
the frequency and height of boost received in our study
population, all 21 radiotherapy institutes in the Netherlands
were contacted and radiation oncologists were questioned
about their institute’s treatment policy in 2003–2008.
Sixteen (76.2%) responded and all reported to have used a
boost in patients with focally positive margins in whom re-
excision was omitted with a median of 20 Gy (range
14–26 Gy). In patients with focally positive margins in
whom re-excision was performed, one institute reported
never to have used a boost after 2004, seven institutes
always used boost, and eight institutes omitted boost in
older patients and/or took into account grade and lym-
phovascular invasion. If boost was given, the median dose
was 16 Gy (range 14–26 Gy). Radiotherapy boost is not
without costs both financial and cosmetic and often addi-
tional hospital visits are needed. Increasing dose is asso-
ciated with increasing incidence of fibrosis [20]. However,
no evidence is available determining if boost or re-excision
is the least harmful or preferred by the patient.
The safety of omitting re-excision in case of focally
positive margins could also be explained by increasing
systemic therapy use and effectiveness over time which
significantly improved local control after breast-conserving
therapy. The 5-year local recurrence rate decreased from
9.8% in 1988–1998 to 3.3% in 2006–2010 in early stage
breast cancer patients B40 years [21]. Moreover, in
patients with focally positive margins, Park et al. described
a local recurrence risk of 7% with systemic therapy as
compared to 18% without systemic therapy [5]. Other
studies evaluating the effect of systemic therapy in patients
with focally positive margins do not exist as far as we
know. In our study, 5-year IBTR rates in patients with
focally positive margins in whom re-excision was omitted
were low and not statistically significantly different both in
the presence and absence of systemic therapy (2.8 and
3.2%, respectively), but the confidence intervals were wide
due to low number of events. Progress in breast cancer
screening and treatment including use of modern radio-
therapy techniques, more effective systemic therapy,
accurate radiological tumor localization, inking of surgical
specimens, and adequate pathological examination of
resection margins may explain why omitting re-excision
for focally positive margins appears to be safe nowadays.
Firm conclusions cannot be drawn, since limitations
apply to our retrospective study. Registration of resection
margins was not mandatory for the registration clerks of
the Netherlands Cancer Registry and was only available in
32.5% of the total study population. The availability of
resection margins was not associated to a time period,
hospitals, pathologists, or IBTR. Moreover, patients in
whom resection margins was registered were comparable
as far as patient, tumor and treatment characteristics are
concerned (data not shown) and the incidence of focally
positive margins was equal to a study of all breast-con-
serving surgeries for invasive cancer in 2012–2013 in the
Netherlands (10.3 and 11.0%) [22]. This confirms that the
subcohort is a random selection from the total study pop-
ulation. The caregivers motives for omitting or performing
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re-excision were unknown, which could have led to con-
founding. However, patients who did and who did not
underwent re-excision for focally positive margins were
comparable as far as patient, tumor and treatment charac-
teristics are concerned (Table 3) and adjustment for all
these possible confounders was performed in the multi-
variable analyses. This makes selection bias less likely,
although unknown residual confounding may be present. A
survey evaluating surgeons’ preferences for margins and
re-excision found that—even though the new SSO-ASTRO
guideline advises against re-excision in case of negative
margin—12% would re-excise for triple-negative tumor
within 1 mm, 50% would re-excise when imaging and
pathology are discordant, when tumor was within 1 mm of
multiple margins, and when multiple foci of DCIS exten-
ded to within 1 mm of multiple margins [23]. Similar
considerations will apply to the Dutch clinical practice.
Another limitation was the limited number of events
impairing to study the effect of omitting re-excision in
clinically relevant subgroups. Furthermore, the orientation
of the involved margins was unknown, but it can be
assumed that re-excision was omitted for anterior and
posterior margin involvement if the standard full thickness
breast tissue excision was performed which previously has
been shown to result in satisfactory local control [24].
Another important issue is the incidence of a first IBTR
after 5 years of follow-up, especially in the estrogen-re-
ceptor-positive tumors, and the changes in prognostic
factors for IBTR related to the time of follow-up [25] [26].
This emphasizes the importance of longer follow-up to
estimate effect of re-excision accurately.
Since a randomized controlled trial of surgical margins
has never been performed and is unlikely to be realizable,
reliance on observational data is an acceptable approach.
No studies have been performed comparing prognosis in
patients in whom the focally positive margin is defined
after the first surgery and thus comparing a group without
re-excision to a group with re-excision after first surgery.
Moreover, this is the first nationwide population-based
analysis on a detailed cancer registry database including all
hospitals, enabling adjustment for confounders. We
describe a 10–100 times larger study population as com-
pared to previous studies even in an era with lower inci-
dence of positive margins, an important strength our study.
It is the first cohort completely treated in the 21st century
approaching current daily practice in which large
improvements in breast cancer treatment and overall
prognosis have been accomplished.
Omitting re-excision in invasive breast cancer patients
with focally positive margins after BCS does not impair
DFS and OS. Provided that adjuvant whole-breast irradia-
tion is given including boost to the tumor bed, more evi-
dence is needed to confirm that IBTR is not impaired
either. Adoption of this recommendation will lead to less
re-excisions and mastectomies which have considerable
clinical implications reducing patient discomfort, health-
care costs, and possibly improvement of cosmetic result.
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